Page 93 - Clinical Development News Today

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2023 Earnings Call Transcript August 10, 2023 Panbela Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.00795 EPS, expectations were $4.71. Operator: Greetings and welcome to the Panbela Therapeutics Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference […]

$48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025Fully prepaid and retired debt facilityAuthorized $7.5 million stock repurchase programLA JOLLA, Calif.--(BUSINESS WIRE)--$EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding...

PDF Version MORRISVILLE, N.C.- August, 8 2023 - Syneos Health® , a leading fully integrated biopharmaceutical solutions organization, today announced it has entered into an... -Today at 10:47 am- MarketScreener

PDF Version MORRISVILLE, N.C.- August 10, 2023 - Syneos Health® a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an... -Today at 10:53 am- MarketScreener

Chronic hives could be treated effectively, conveniently, and rapidly after positive results from a clinical trial by Novartis produced positive top line results.

The first patient has been enrolled in a phase 3 clinical trial of leniolsib a treatment for a rare inherited condition affecting how the immune system works.

/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...

International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis patients with accompanying systemic inflammatory response syndrome , in India Expansion of team with key... -Today at 04:08 pm- MarketScreener

/PRNewswire/ -- DelveInsights Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices,...

Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.